Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma

Current Opinion in Orthopaedics

Volumn 14, Issue 6, 2003, Pages 419-428

  Jimeno, Jose ^a   Maki, Robert G ^c   Casali, Paolo ^d   Faircloth, Glynn ^b   Martinez, Nerea ^e   Nieto, Antonio ^a   Cañigueral, Salvador ^f   Rinehart, Kenneth ^g  

^a PHARMAMAR S A   (Spain)

^b PharmaMar USA Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Structural Biology and Biocomputing Programme   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

ET 743; Marine compound; Sarcoma

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TRABECTEDIN;

ADULTHOOD; AGE DISTRIBUTION; ALOPECIA; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DNA REPAIR; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG ISOLATION; DRUG MECHANISM; DRUG PROGRAM; DRUG SAFETY; DRUG STRUCTURE; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; HEPATOBILIARY DISEASE; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LIVER TOXICITY; MARINE ENVIRONMENT; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; TOXICITY; TRANSAMINITIS; TREATMENT OUTCOME; VOMITING;

EID: 0242522296     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-200312000-00011     Document Type: Review

References (50)

1. Singer S, Demetri G, Baldini E, et al.: Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000, 1:75-85.
2. Blay JY, Van Glabbeke M, Verweij J, et al.: Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003, 39:64-69. This article includes a large and in-depth descriptive analysis of the natural history of metastatic STS. The availability of the largest database from the Soft Tissue and Bone Sarcoma Group for this analysis confers a high level relevance to the results generated, which clearly confirm that a subset of patients can reach long-term survival.
3. Guan Y, Sakai R, Rinehart KL, et al.: Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993, 10:793-818.
4. Pommier Y, Kohlhagen G, Bailly C, et al.: DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35:13303-13309.
5. Moore BM II, Seaman FC, Hurley LH: NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 1997, 119:5475-5476.
6. Minuzzo M, Marchini S, Broggini M, et al.: Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc Natl Acad Sci U S A 2000, 97:6780-6784.
7. Jin S, Gorfajn B, Faircloth G, et al.: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 2000, 97:6775-6779.
8. Friedman D, Hu Z, Kolb EA, et al.: Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002, 62:3377-3381. This article corroborates the idea that trabectidin affects the transcription of activated genes.
9. Erba E, Bergamaschi D, Bassano L, et al.: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001, 37:97-105.
10. Jimeno JM, Faircloth G, Cameron L, et al.: Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743). Drugs Fut 1996, 21:1155-1165.
11. Izbicka E, Lawrence R, Raymond E, et al.: In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998, 9:981-987.
12. Valoti G, Nicoletti MI, Pellegrino A, et al.: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998, 4:1977-1983.
13. Hendriks Hr, Fiebig Hh, Glavazzi R, et al.: High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999, 10:1233-1240.
14. Li WW, Takahashi N, Jhanwar S, et al.: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001, 7:2908-2911.
15. Scotlandi K, Perdichizzi S, Manara MC, et al.: Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002, 8:3893-3903. This article indicates that trabectidin is particularly active in cell lines derived from Ewing sarcoma and shows that the pattern of resistance is different from that of other drugs. In addition, the article provides indication of synergism with other anticancer drugs.
16. Kanzaki A, Takebayashi Y, Ren XQ, et al.: Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 2002, 1:1327-1334. This article confirms the impact of ET-743 in the MDR1 path and also provides a further rationale for studies in combination therapy.
17. Takahashi N, Li WW, Banerjee D, et al.: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001, 7:3251-3257.
18. Meco D, Colombo T, Ubezio P, et al.: Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003, 52:131-138. This article validates in vivo the rationale to combine ET-743 with doxorubicin.
19. Takebayashi Y, Pourquier P, Zimonjic DB, et al.: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001, 7:961-966.
20. Damia G, Silvestri S, Carrassa L, et al.: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001, 92:583-588.
21. D'Incalci M, Colombo T, Ubezio P, et al.: The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003, 39:1920-1926. This article shows that the combination of trabectidin and cisplatin induces antitumor responses in xenografts that are much greater than responses with each drug alone, without overlapping toxicity.
22. Taamma A, Misset JL, Riofrio M, et al.: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001, 19:1256-1265.
23. Ryan DP, Supko JG, Eder JP, et al.: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001, 7:231-242.
24. Villalona-Calero MA, Eckhardt SG, Weiss G, et al.: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002, 8:75-85.
25. Twelves C, Hoekman K, Bowman A, et al.: Phase I and pharmacokinetic study of Yondelis (ecteinascidin 743; ET-743) administered as an infusion over 1h or 3h every 21 days in patients with solid tumors. Eur J Cancer 2003, 39:1842-1851. This article extensively describes the therapeutic index of the 3-hour intravenous schedule currently being investigated in advanced STS.
26. Rosing H, Hillebrand MJ, Jimeno JM, et al.: Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 1998, 33:1134-1140.
27. Van Kesteren C, Cvitkovic E, Taamma A, et al.: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000, 6:4725-4732.
28. Forouzeh B, Hildago M, Denis L, et al.: phase I and pharmacokinetic study of the marine-derived DNA minor groove binder ET-743 on a weekly x3 every-4-week schedule in patients with advanced solid malignancies. In Proc of AACR-NCI-EORTC International Conference on Molecul Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. Miami Beach, FL: 2001:42.
29. Baruchel S, Blaney S, Hershon L, et al.: A phase I study of ET-743 in pediatric refractory solid tumors: a Children's Oncology Group Study. Proc Am Soc Clin Oncol 2002, 21:96a (Abstract 381).
30. Gomez J, Lopez-Lazaro L, Guzman C, et al.: Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Pro Am Soc Clin Oncol 2000, 19:187.
31. Lopez-Martin JA, Nieto A, Demetri GD, et al.: Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials (CT) in adult patients with solid tumors. Proc Am Soc Clin Oncol 2002, 21:96a (Abstract 382).
32. Demetri GD, Manola J, Harmon D, et al.: Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): final results of phase II and pharmacokinetic studies in the U.S.A. Proc Am Soc Clin Oncol 2001, 20:352a.
33. Le Cesne A, Blay J, Judson I, et al.: ET-743 is an active drug in adult soft-tissue sarcoma (STS): a STBSG-EORTC phase II trial. Proc Am Soc Clin Oncol 2001, 20:353a.
34. Yovine A, Riofrio M, Brain E, et al.: Ecteinascidin (ET-743) given as a 24 hour (H) intravenous continuous infusion (IVCI) every 3 weeks: results of a phase II trial in patients (pts) with pretreatment soft tissue sarcomas (PSTS). Proc Am Soc Clin Oncol 2001, 20:363a.
35. Lopez Martin JA, Verweij J, Blay J, et al.: An exploratory analysis of tumor growth rate (TGR) variations induced by trabectidin (ecteinascidin-743) in patients (pts) with pretreated advanced soft tissue sarcoma (PASTS). ASCO 39th Annual Meeting Proc Book Vol. 22, Abs. 3293, pp. 819. Chicago, IL, May 31-June 3, 2003.
36. Dileo P, Casali PG, Bacci G, et al.: Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proc Am Soc Clin Oncol 2002, 21:408a.
37. George S, Maki RG, Harmon D, et al.: Phase II study of ecteinascidin-743 (ET-743) given by 3-hour IV infusion in patients (pts) with soft tissue sarcomas (STS) failing prior chemotherapies. Proc Am Soc Clin Oncol 2002, 21:408a.
38. Delaloge S, Yovine A, Taamma A, et al.: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001, 19:1248-1255.
39. Laverdiere C, Kolb A, Supko J, et al.: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003, 98:832-840. This article established the basis to investigate ET-743 in minimally pretreated advanced bone sarcoma.
40. Harris MB, Cantor AB, Goorin AM, et al.: Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995, 24:87-92.
41. Ryan D, Puchalski T, Supko J, et al.: A phase II and pharmacokinetic study of ecteinascidin 743, in patients with gastrointestinal stromal tumors. Oncologist 2002, 7:531-538.
42. Casanova M, Casali P, Sessa C, et al.: Phase II study of 3-hours infusion ecteinascidin-743 (ET-743) in pretreated adult and pediatric patients with advanced or recurrent sarcomas: preliminary results. Proc SIOP 2002, 257.
43. Grasselli G, Malossi A, Colombo N, et al.: Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, trabectidin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. ASCO 39th Annual Meeting Proc Book, Vol. 22, Abs. 542, pp. 135. Chicago, IL, May 31-June 3, 2003.
44. Van Glabbeke M, Verweij J, Judson I, et al.: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549. This important analysis reinforces the value of tumor control as a surrogate endpoint in clinical studies in STS. It also validates the clinical impact of long-lasting stabilization of the disease in the definition of active drugs in STS.
45. Morioka H, Weissbach L, Vogel T, et al.: Antiangiogenensis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003, 9:1211-1217. A very elegant experimental article demonstrating the potential impact of novel combinations against sarcoma.
46. Borden E, Baker L, Bell R, et al.: Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003, 9:1941-1956. A thorough review of molecular pathology in the implementation of new therapeutic strategies in sarcoma.
47. Sarries C, Haura E, Roig B, et al.: Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002, 3:763-780. An essential reading for the potential tools available for customized therapies in cancer. Many of the elaborations included in this article may be applicable in the treatment of sarcoma.
48. Taron M, Alberola V, Sarries C, et al.: XPD polymorphisms identify a subset of non-small cell lung cancer (NSCLC) patients with poor survival with gemcitabine/cisplatin. In Proceedings of the 10th World Conference on Lung Cancer, 10-14 August 2003. Vancouver, Canada: 2003:(abs O-47).
49. Gurubhagavatula S, Liu G, Park S, et al.: Polymorphisms of DNA repair and xenobiotic metabolism genes affect overall survival in advanced non small cell lung cancer patients treated with platinum agents. In Proceedings of the 10th World Conference on Lung Cancer, 10-14 August 2003. Vancouver, Canada: 2003:(abs O-171).
50. Tracey L, Villuendas R, Dotor AM, et al.: Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003, 102:1042-1050. An interesting article on the real clinical impact of the gene expression profiling in cancer therapy.